Questcor Update: Largest Privately Owned Pharmacy Benefits Manager Study Finds 96% of Acthar Prescriptions Unnecessary
Another Step Towards Questcor's Inevitable Endgame
Today, Citron shares a new key data point, so far overlooked by Wall Street. This one is from Prime Therapeutics, the largest privately-held PBM in the United States, as well as a thought leader in pharmacy benefit management strategies. Their partnership with Blue Cross and Blue Shield covers 20 million people nationwide with an annual drug spend of $12.4 billion. Prime recently issued a case study summary with regard to Acthar Gel prescriptions. Its write-up of a study of 30 Acthar prescriptions states : "Analysis Finds 96% of Use Unnecessary".
This aligns Prime with Aetna's increasingly restrictive coverage policies on Acthar, disclosed just a few weeks ago.